C4 Therapeutics (CCCC) Non Operating Income (2019 - 2026)

C4 Therapeutics' Non Operating Income history runs 8 years deep, the most recent figure standing at $2.7 million for Q1 2026.

• In Q1 2026, Non Operating Income fell 6.54% year-over-year to $2.7 million; the TTM figure through Mar 2026 stood at $10.2 million (down 24.23% YoY), while the FY2025 annual figure was $10.3 million, down 28.28% from the prior year.
• Non Operating Income was $2.7 million for Q1 2026 at C4 Therapeutics, down from $2.8 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $3.9 million in Q1 2024 to a low of -$251000.0 in Q1 2022.
• Historically, Non Operating Income has averaged $2.2 million across 5 years, with a median of $2.5 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Non Operating Income jumped 5978.57% in 2023, then sank 37.23% in 2025.
• A 5-year view of Non Operating Income shows it stood at $1.1 million in 2022, then surged by 166.25% to $2.9 million in 2023, then increased by 10.75% to $3.3 million in 2024, then dropped by 14.91% to $2.8 million in 2025, then fell by 4.46% to $2.7 million in 2026.
• The last three Non Operating Income figures came in at $2.7 million (Q1 2026), $2.8 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.